Weekly OHDSI Digest - 24Jul2017

MauraBeaton · July 24, 2017, 9:03pm

OHDSI MEETINGS THIS WEEK

Pharmacovigilance evidence investigation workgroup meeting - Wednesday at 9am ET
https://global.gotomeeting.com/join/530277469

Population-Level Estimation (Eastern hemisphere) workgroup meeting - Wednesday at 3pm Hong Kong time
https://meetings.webex.com/collabs/#/meetings/detail?uuid=M6WE9AOKFETH2VEFPVCZWWBIT0-D1JL&rnd=345959.95335

Patient-level prediction (Western hemisphere) WG Meeting - Wednesday at 12pm ET
https://global.gotomeeting.com/join/9729176611

Architecture WG meeting - Thursday at 1pm ET
Webex: https://jjconferencing.webex.com/mw3000/mywebex/default.do?service=1&main_url=%2Fmc3000%2Fe.do%3Fsiteurl%3Djjconferencing%26AT%3DMI%26EventID%3D283835502%26MTID%3Dmb7e839a762fbdaab0608f27500679223%26Host%3DQUhTSwAAAASTOYBxx2KWYTIL7ZSgHgHJoIHctjgxp8k5mgqAEPo2a1ESa12-8hjAVWbZznuDt96ugkT31G8sY5iSWLRwSwhI0%26FrameSet%3D2&siteurl=jjconferencing&nomenu=true

ANNOUNCEMENTS

OHDSI in China The China WG will be meeting on August 21st in Hangzhou, China (during MedInfo). More details: http://www.ohdsi.org/web/wiki/doku.php?id=projects:workgroups:china-wg

2017 OHDSI Symposium Registration - Registration for the 2017 OHDSI symposium is now open! Please register here: https://www.ohdsi.org/symposium-registration/
PLEASE NOTE: Registration is for the main symposium only (set to take place on October 18th). Registration for tutorials (set to take place on October 19-20th) is separate.

2017 OHDSI Tutorials Registration - Registration for OHDSI tutorials is now open! Information about each tutorial, including topics covered, faculty and prerequisites can be found here: https://www.ohdsi.org/about-event-tutorials/
Register here: https://www.ohdsi.org/tutorial-registration/

2017 OHDSI Symposium Accommodation - This year’s symposium will take place at the Bethesda North Marriott, just outside Washington DC. If you’d like to stay at the Marriott during the symposium we suggest booking your stay as soon as possible. October is a busy month in DC.
http://www.marriott.com/hotels/travel/wasbn-bethesda-north-marriott-hotel-and-conference-center/
Possible discounted rate: For details about getting a lower room rate at the Marriott, check out @krfeeney’s forum post: 2017 OHDSI Symposium - Resources for hotel bookings

Call for Sponsorship - To fund the 2017 symposium we need to raise $200K to cover operating costs of venue rental, lunch, audio/visuals and recordings fees. We’re reaching out to the entire community for sponsors who want to support this important event and allow us to build upon the success of past symposia. More details: OHDSI Symposium 2017 - call for sponsorship

Updating OHDSI.org - Over the next couple months we’ll be updating collaborator profiles and our data network list. If you have updates you’d like made to your OHDSI profile, or have updated information about your database, please email beaton@ohdsi.org with the changes.

Simplicity is the ultimate sophistication.

Leonardo da Vinci

COMMUNITY PUBLICATIONS

Risk of angioedema associated with levetiracetam compared with phenytoin: Findings of the observational health data sciences and informatics research network
http://onlinelibrary.wiley.com/doi/10.1111/epi.13828/full

Learning Effective Treatment Pathways for Type-2 Diabetes from a clinical data warehouse.

ncbi.nlm.nih.gov

Learning Effective Treatment Pathways for Type-2 Diabetes from a clinical data warehouse.

R Vashisht, K Jung and N Shah, AMIA ... Annual Symposium proceedings. AMIA Symposium, 2016

Treatment guidelines for management of type-2 diabetes mellitus (T2DM) are controversial because existing evidence from randomized clinical trials do not address many important clinical questions. Data from Electronic Medical Records (EMRs) has been used to profile first line therapy choices, but this work did not elucidate the factors underlying deviations from current treatment guidelines and the relative efficacy of different treatment options. We have used data from the Stanford Hospital to attempt to address these issues. Clinical features associated with the initial choice of treatment were effectively re-discovered using a machine learning approach. In addition, the efficacies of first and second line treatments were evaluated using Cox proportional hazard models for control of Hemoglobin A1c. Factors such as acute kidney disorder and liver disorder were predictive of first line therapy choices. Sitagliptin was the most effective second-line therapy, and as effective as metformin as a first line therapy.

Formalizing drug indications on the road to therapeutic intent

The novel use of an Extreme learning machines for clinical decision support systems.

The Concomitant Association of Thyroid Disorders and Myasthenia Gravis.

ncbi.nlm.nih.gov

The Concomitant Association of Thyroid Disorders and Myasthenia Gravis.

YP Lin, U Iqbal, PA Nguyen, MM Islam, S Atique, WS Jian, YJ Li, CL Huang and CH Hsu, Translational neuroscience, 2017

Some of the thyroid disorders (TD) and Myasthenia gravis (MG) are autoimmune related disease. The purpose of the study to evaluate the relationship of MG with all morphological and functional thyroid disorders.We constructed a population-based cohort study during the period from January 2000-December 2002 by using reimbursement data from the Bureau National Health Insurance (NHI) system in Taiwan. Patients with TD and MG were identified by referring to the ICD-9-CM codes. (ICD-10-CM as reference) .The association of TD with MG occurred only in the same person within the study period. The Q value was used to measure the strength of disease-disease associations.We obtained 520628 TD and 7965 MG records for analysis. Diffuse toxic goiter had highest association rate, followed by nontoxic nodular goiter, simple goiter, chronic lymphocytic thyroiditis, thyroid cancer, and toxic nodular goiter. Female and older patients had a higher rate than their male and younger counterparts, respectively. Functional abnormalities revealed higher incidence of thyrotoxicosis and hypothyroidism in both sexes. We also found the strongest association in men with chronic thyroiditis, diffuse toxic goiter, thyrotoxicosis, acquired hypothyroidism, thyroid cancer, and simple goiter. While an intermediate association was observed in female with diffuse toxic goiter, in a male with toxic and nontoxic nodular/multinodular goiters, in female with thyrotoxicosis, thyroid cancer and acquired hypothyroidism.This population based cohort study showed potential association of all types of TD with MG, and observed a higher association rate in female autoimmune TD whereas males showed a higher strength of association.